Tumor and Transplant Immunology

  • Sean C. Kumer
  • Kenneth L. Brayman
Part of the Springer Specialist Surgery Series book series (SPECIALIST)


The realm of immunology encompasses basic science and clinical applied medicine. It continues to evolve from its initial studies of innate immunity and resulting physiologic response. Its entirety includes the primary therapy of cancers and the modulation of the immune system in cancer therapy as well as the suppression during transplantation to prevent recognition of non-self.


Major Histocompatibility Complex Acute Rejection Induction Therapy Mycophenolate Mofetil Major Histocompatibility Complex Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Old LJ. Immunotherapy for cancer. Sci Am. 1996;275:136-143PubMedCrossRefGoogle Scholar
  2. 2.
    Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991;262:3-11PubMedGoogle Scholar
  3. 3.
    Berkow R, Beers MH. Cancer and the immune system. In: The Merck Manual of Medical Information. White- house Station, NJ: Merck Research Laboratories; 1997: 792-794Google Scholar
  4. 4.
    Zeir M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis. 2002;39:E5CrossRefGoogle Scholar
  5. 5.
    Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 1990;29:545-550PubMedCrossRefGoogle Scholar
  6. 6.
    Guyton AC, Hall JE, eds. Immunity, allergy, blood groups, and transfusion. In: Human Physiology and Mechanisms of Disease. 6th ed. Philadelphia, PA: W.B. Saunders Company;1997:291-293Google Scholar
  7. 7.
    Guyton AC, Hall JE, eds. Resistance of the body to infection: II. Immunity and allergy. In: Textbook of Medical Physiology. 10th ed. Philadelphia, PA: W.B. Saunders Company;2000: 408-410Google Scholar
  8. 8.
    Brennan D. Faith supported by reason: mechanistic support for the use of polyclonal antibodies in transplantation. Transplantation. 2003;75:577PubMedCrossRefGoogle Scholar
  9. 9.
    von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med. 2003; 343:1020Google Scholar
  10. 10.
    Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Blood. 1998;91:2360PubMedGoogle Scholar
  11. 11.
    Préville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation. 2001;71:460PubMedCrossRefGoogle Scholar
  12. 12.
    Gill JS, Tonelli M, Mix CH, et al. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int. 2004;65(2):692-699PubMedCrossRefGoogle Scholar
  13. 13.
    Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation. 2001;72(2): 245-250PubMedCrossRefGoogle Scholar
  14. 14.
    Mourad G, Garrigue V, Squifflet JP, et al. Induction versus non induction in renal transplant recipients with tacrolimus-based imunosuppression. Transplantation. 2001;72(6):1050-1055PubMedCrossRefGoogle Scholar
  15. 15.
    Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc. 2003;35(suppl 3):25S-34SPubMedCrossRefGoogle Scholar
  16. 16.
    Pescovitz MD, Govani M. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis. 2001;38(4 suppl 2):S16-S21PubMedCrossRefGoogle Scholar
  17. 17.
    Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481-492PubMedCrossRefGoogle Scholar
  18. 18.
    Shapiro R, Nalesnik M, McCauley J. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999;68(12):1851-1854PubMedCrossRefGoogle Scholar
  19. 19.
    Srivastava T, Zwick DL, Rothberg PG. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol. 1999;13(9):748-754PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Sean C. Kumer
    • 1
  • Kenneth L. Brayman
    • 1
  1. 1.Division of Transplant Surgery, Department of SurgeryUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations